AR033426A1 - Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento - Google Patents
Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimientoInfo
- Publication number
- AR033426A1 AR033426A1 ARP020100698A ARP020100698A AR033426A1 AR 033426 A1 AR033426 A1 AR 033426A1 AR P020100698 A ARP020100698 A AR P020100698A AR P020100698 A ARP020100698 A AR P020100698A AR 033426 A1 AR033426 A1 AR 033426A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- movement disorders
- alkyl
- prevention
- treatment
- Prior art date
Links
- 208000016285 Movement disease Diseases 0.000 title abstract 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un método para prevenir o tratar trastornos del movimiento que comprende la administracion a un sujeto que así lo requiera, de una cantidad terapéuticamente efectiva de un compuesto seleccionado del grupo consistente de la formula (1) y de la formula (2), en las cuales: el grupo fenilo está sustituido en X con 1-5 átomos de halogenos seleccionados del grupo que consiste de fluor, cloro, bromo y yodo; y R1, R2, R3, R4, R5 y R6 son seleccionados independientemente del grupo que consiste de hidrogeno y alquilo C1-4; en el cual el alquilo C1-4 está opcionalmente sustituido con fenilo (en el cual, el fenilo está opcionalmente sustituido con sustituyentes independientemente seleccionados del grupo que consiste de halogeno, alquilo C1-4, alcoxi C1-4, amino, nitro y ciano).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168301P | 2001-02-27 | 2001-02-27 | |
| US10/081,501 US6589985B2 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033426A1 true AR033426A1 (es) | 2003-12-17 |
Family
ID=26765643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100698A AR033426A1 (es) | 2001-02-27 | 2002-02-27 | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6589985B2 (es) |
| EP (1) | EP1411917B1 (es) |
| JP (1) | JP2004527492A (es) |
| KR (1) | KR100858232B1 (es) |
| CN (1) | CN1262272C (es) |
| AR (1) | AR033426A1 (es) |
| AT (1) | ATE369130T1 (es) |
| AU (1) | AU2002247204B2 (es) |
| BR (1) | BR0207831A (es) |
| CA (1) | CA2439478C (es) |
| CY (1) | CY1106924T1 (es) |
| CZ (1) | CZ20032299A3 (es) |
| DE (1) | DE60221670T2 (es) |
| DK (1) | DK1411917T3 (es) |
| ES (1) | ES2291454T3 (es) |
| HU (1) | HUP0303344A3 (es) |
| IL (2) | IL157592A0 (es) |
| MX (1) | MXPA03007719A (es) |
| MY (1) | MY157373A (es) |
| NO (1) | NO20033803L (es) |
| NZ (1) | NZ551954A (es) |
| PL (1) | PL364679A1 (es) |
| PT (1) | PT1411917E (es) |
| RS (1) | RS50676B (es) |
| RU (1) | RU2294739C2 (es) |
| TW (1) | TWI331524B (es) |
| WO (1) | WO2002067926A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003445A3 (cs) * | 2000-07-21 | 2004-08-18 | Ortho@Mcneilápharmaceuticalźáinc | Karbamátové sloučeniny pro prevenci nebo léčbu neuropatické bolesti a bolesti asociované s histaminovou a migrenózní bolestí hlavy |
| MXPA03007718A (es) * | 2001-02-27 | 2004-11-12 | Johnson & Johnson | Compuestos de carbamato para usarse en la prevencion o tratamiento de trastornos neurodegenerativos. |
| NZ549752A (en) | 2001-07-16 | 2008-04-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| US8440715B2 (en) | 2005-06-08 | 2013-05-14 | Sk Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
| AU2005335241B9 (en) * | 2005-07-26 | 2012-12-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating substance-related disorders |
| MX2009004798A (es) * | 2006-10-31 | 2009-08-12 | Janssen Pharmaceutica Nv | Tratamiento de los trastornos generalizados del desarrollo. |
| US8927602B2 (en) | 2009-11-06 | 2015-01-06 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| KR101783632B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법 |
| US8623913B2 (en) * | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| WO2014142477A1 (en) * | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes |
| WO2014142549A1 (en) | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| KR102635941B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| MY203401A (en) | 2017-06-02 | 2024-06-26 | Jazz Pharmaceuticals Ireland Ltd | Methods and compositions for treating excessive sleepiness |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| CA3191072A1 (en) | 2020-08-31 | 2022-03-03 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
-
2002
- 2002-02-21 WO PCT/US2002/005542 patent/WO2002067926A1/en not_active Ceased
- 2002-02-21 KR KR1020037011271A patent/KR100858232B1/ko not_active Expired - Fee Related
- 2002-02-21 DE DE60221670T patent/DE60221670T2/de not_active Expired - Lifetime
- 2002-02-21 DK DK02714978T patent/DK1411917T3/da active
- 2002-02-21 EP EP02714978A patent/EP1411917B1/en not_active Expired - Lifetime
- 2002-02-21 ES ES02714978T patent/ES2291454T3/es not_active Expired - Lifetime
- 2002-02-21 JP JP2002567293A patent/JP2004527492A/ja active Pending
- 2002-02-21 CA CA2439478A patent/CA2439478C/en not_active Expired - Fee Related
- 2002-02-21 AT AT02714978T patent/ATE369130T1/de active
- 2002-02-21 RU RU2003128985/14A patent/RU2294739C2/ru not_active IP Right Cessation
- 2002-02-21 CZ CZ20032299A patent/CZ20032299A3/cs unknown
- 2002-02-21 IL IL15759202A patent/IL157592A0/xx unknown
- 2002-02-21 PT PT02714978T patent/PT1411917E/pt unknown
- 2002-02-21 NZ NZ551954A patent/NZ551954A/en unknown
- 2002-02-21 MX MXPA03007719A patent/MXPA03007719A/es active IP Right Grant
- 2002-02-21 RS YUP-677/03A patent/RS50676B/sr unknown
- 2002-02-21 AU AU2002247204A patent/AU2002247204B2/en not_active Ceased
- 2002-02-21 US US10/081,501 patent/US6589985B2/en not_active Expired - Fee Related
- 2002-02-21 HU HU0303344A patent/HUP0303344A3/hu unknown
- 2002-02-21 PL PL02364679A patent/PL364679A1/xx not_active Application Discontinuation
- 2002-02-21 BR BR0207831-7A patent/BR0207831A/pt not_active Application Discontinuation
- 2002-02-21 CN CNB028089243A patent/CN1262272C/zh not_active Expired - Fee Related
- 2002-02-27 MY MYPI20020692A patent/MY157373A/en unknown
- 2002-02-27 AR ARP020100698A patent/AR033426A1/es unknown
- 2002-02-27 TW TW091103503A patent/TWI331524B/zh not_active IP Right Cessation
-
2003
- 2003-08-26 NO NO20033803A patent/NO20033803L/no not_active Application Discontinuation
- 2003-08-26 IL IL157592A patent/IL157592A/en not_active IP Right Cessation
-
2007
- 2007-10-10 CY CY20071101301T patent/CY1106924T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| AR033427A1 (es) | Uso de compuestos carbamatos en el tratamiento del dolor | |
| AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
| BRPI0515374A (pt) | métodos de tratamento de epileptogenêse e epilepsia | |
| DK1408953T3 (da) | Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom | |
| MY133370A (en) | Carbamate compounds for use in preventing or treating bipolar disorders | |
| AR032876A1 (es) | Compuestos de carbamato para utilizar en la prevencion o tratamiento de los trastornos psicoticos | |
| PT1399144E (pt) | Compostos carbamato para utilizacao na prevencao ou tratamento de disturbios de ansiedade | |
| AR052885A1 (es) | Metodos para el control del intervalo qt | |
| AR054550A1 (es) | Metodos para tratar la epileptogenesis | |
| PT1305082E (pt) | Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca | |
| AR032907A1 (es) | Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad | |
| AR033428A1 (es) | Compuestos carbamatos para su uso en la prevencion o tratamiento de trastornos bipolares | |
| DK1408954T3 (da) | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af neuropatisk smerte | |
| AR034785A1 (es) | Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada | |
| AR035757A1 (es) | Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| AR034786A1 (es) | Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada | |
| AR033545A1 (es) | Uso de compuestos de carbamato para la fabricacion de medicamentos | |
| MY136347A (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |